Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clini
Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervent
| Condition(s) | Behavioral Intervention, Viral Suppression of HIV Infection, ART Adherence |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Men who are living with HIV and use stimulants face many challenges and barriers that may interfere with remembering to take their HIV medication. Forgetting to take HIV medication puts men living with HIV at a greater risk of becoming virally unsuppressed. Researchers are doing this study to test if a remote intervention can help participants improve remembering to take their HIV medications and reduce the HIV viral load among men living with HIV who use stimulants. |
| Who can participate | Inclusion Criteria: * Prescribed antiretroviral therapy (ART) with a tenofovir-based regimen. * Documented virologic non-suppression, urine tenofovir testing without tenofovir detected, or self-reported adherence \<100%. * Reports stimulant use. * Has a mailing address within the U.S. * Currently has a smartphone with photo capabilities. Exclusion Criteria: * Have any health condition that may interfere with participation or the ability to provide informed consent, including any debilitating or life-threatening conditions. * Not prescribed ART. * Unwilling to perform urine self-testing or to attend a local Quest site for viral load monitoring. * Unable to provide a hair sample of \~50-100 strands of hair that are non-gray, not bleached, and at least 1cm in length |
| Ages | 18 Years to 70 Years |
| Sex | Male |
| Lead sponsor | University of California, San Francisco |
| Locations | San Francisco, California, United States |
| Start date | 2026-02-09 |
| NCT ID | NCT07125235 |
| Official listing | https://clinicaltrials.gov/study/NCT07125235 |